PeptideStack
5.2kquestions
20kanswers
220users

Does oral semaglutide adsorb measurably to the vial wall at 6.67 mg/mL?

Asked 14 Oct 2025Modified 8 months agoViewed 14k times
19

The particulars: oral semaglutide · 6.67 mg/mL.

I would like the arithmetic checked rather than the conclusion asserted.

I have deliberately not used an online calculator because I want to be able to check the result.

Can someone show the working rather than just the answer?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

438 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

646 questions
shareeditfollowflag
VR
askedvalentina_rossi16k2814 Oct 2025

3 Answers

Accepted answer first, then by votes
-3

Accepted answer

Degradation is not one process, and which one dominates depends on the condition you are asking about. In solution at refrigerated temperature the rate-limiting pathway is usually deamidation and hydrolysis; at room temperature aggregation overtakes them; frozen, the damage happens during the transitions rather than during the hold.

Aggregation is the failure mode that reverse-phase HPLC is worst at detecting, because a large soluble aggregate may not elute at all and an insoluble one is filtered out during sample preparation. If your purity result comes back normal but the vial looks hazy, believe the vial. Size-exclusion chromatography is the method that sees this.

Practical thermal arithmetic for a shipment: a single 250 g phase-change pack in a thin-walled polystyrene box holds sub-ten-degrees for roughly 24 to 48 hours in a 25 °C ambient, and considerably less at 35 °C. Any lane taking eight to fourteen days is therefore not temperature-controlled for most of its duration regardless of what was in the box, which is the argument for shipping the material lyophilised.

Deamidation kinetics for asparagine in peptides are well characterised and strongly sequence-dependent: the residue following the asparagine dominates the rate, with glycine and serine at the n+1 position accelerating it by an order of magnitude relative to bulkier residues. That is why two peptides in the same buffer at the same temperature can have quite different shelf lives.

The limitation is that you cannot detect slow aggregation by eye until it is well advanced, so a clear vial is weak evidence of an intact one.

Store solid, store cold, store dry, and reconstitute what you will use rather than what fits in the vial.

shareimprove this answerflag
TM
answered · acceptedtobias_maartens94k2589 Nov 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
34

Freeze-thaw damage happens at the moving ice front, not at the storage temperature. Once the sample is frozen solid and cold, very little is happening. The damage is done during freezing and thawing, which is why the number of cycles matters and the duration of the hold mostly does not.

A domestic freezer holds roughly minus eighteen degrees and cycles by several degrees on its defrost schedule, which for a lyophilised solid is entirely adequate and for a frozen solution means repeated partial melting at the surface. If you are going to freeze a solution, an unopened chest freezer is materially better than the compartment in the top of a fridge.

Light matters for specific residues rather than in general. Tryptophan and to a lesser extent tyrosine and methionine are photo-labile; a sequence without them is largely indifferent to ambient light over the timescales in question. Amber glass is cheap insurance rather than a requirement.

Where community-submitted samples with known thermal excursions have been tested at Janoshik or Medutest, the recurring finding is that lyophilised material tolerates warm transit far better than intuition suggests, while reconstituted material shipped warm does not. The asymmetry is consistent enough to plan around.

Minimise transitions rather than minimising temperature. One freeze and one thaw is fine; five is a different question.

shareimprove this answerflag
RO
answeredrae_oyelowo21k3821 Nov 2025
The distinction between purity and content cannot be repeated often enough here. – one_ml_bac 4 months ago
add a comment
16

A warm arrival is a reason to test, not automatically a reason to discard. Peptide degradation is kinetic — rate multiplied by time — and a few days at thirty degrees in the solid state is a small integral compared to weeks in solution.

On re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle. If it arrived as a solution that thawed, re-freezing adds a second transition and therefore a second dose of ice-front shear. The asymmetry is worth internalising.

Adsorption to the container is a real loss at low concentration. For a peptide at 0.1 mg/mL in an untreated glass vial, single-digit percentage losses to the wall are plausible; at 5 mg/mL it is negligible. This is one of several reasons not to reconstitute to a very dilute working solution and store it.

One qualification: none of this addresses sterility. A vial can be chemically pristine and microbiologically compromised, and a chromatogram will not tell you which.

The practical rule is that time and temperature multiply, so shorten whichever one you control.

edited 8 Nov 2025 by mz_4113 — removed a claim I could not source

shareimprove this answerflag
M4
answeredmz_411399k25829 Oct 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.